Five years’ experience treating locally advanced cervical cancer with concurrent chemoradiotherapy: results from a single institution
- 26 April 2015
- journal article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 292 (5) , 1091-1099
Abstract
Cervical cancer is the second most common cause of female cancer death. In Morocco it is the second most common cancer, our department recruits more than 500 patients each year and proximally half of the cases are diagnosed at an advanced stage. Between January 2008 and December 2008, all patients with diagnosis of locally advanced cervical cancer referred to our department and treated with concurrent chemoradiotherapy were retrieved. We analyzed outcomes for this particular population; overall survival, local control, and toxicities, we also retrieved prognostic factors influencing outcomes for this population. The overall survival rate for the cohort was 68 % at 2 years, and reached 47 % at 5 years. The overall LC rate was 71 % at 2 years and 58 % at 5 years. The most important prognostic factors for OS and LC were the pretreatment hemoglobin, the tumor size, total duration of treatment, and the use of brachytherapy. For OS, the presence of enlarged lymph nodes was also important. For LC, the number of chemotherapy’s courses was important. Of the included patients, 20 % experienced late grade 3 or 4 toxicity. The results of our study have shown that despite all the treatment strategies available, locally advanced cervical cancer is associated with bad outcomes. In this cohort, the most important prognostic factors were the pretreatment hemoglobin level and the tumor size.Keywords
This publication has 37 references indexed in Scilit:
- Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized TrialsJournal of Clinical Oncology, 2008
- Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapyGynecologic Oncology, 2008
- Global Burden of Disease2008
- The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervixJournal of Gynecologic Oncology, 2008
- Carcinoma of the Cervix UteriInternational Journal of Gynecology & Obstetrics, 2006
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006
- Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancerNature Clinical Practice Oncology, 2006
- Récurrence du cancer du col : facteurs de risque et traitementEMC - Gynécologie, 2006
- Neoadjuvant chemotherapy for locally advanced cervical cancerEuropean Journal of Cancer, 2003
- Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989